Patient Reported Outcomes Measurement Symposium
About the Patient Reported Outcomes Measurement Symposium
18 – 19 October 2012
The EQ-5D is a standardized instrument developed by the EuroQol group for use as a measure of health outcome. It considers five dimensions of health-related quality of life: mobility, self-care, usual activities, pain/discomfort, anxiety/depression.
When the need for greater collaboration around implementation and use of the EQ-5D in Alberta was recognized in eary 2012, colleagues from the HQCA, AHS, the School of Public Health, University of Alberta, and the Institute of Health Economics (IHE) met to explore the feasibility of bringing together key stakeholders in Alberta’s health system to discuss the potential for adopting EQ-5D as a standardized health outcome measure in Alberta.
Download Symposium Proceedings
Patient-Reported Outcomes Measurement in Alberta: Potential of the EQ-5D Symposium Proceedings
The objectives of the symposium were to:
- Develop a common understanding of what the EQ-5D is and the scope of its application internationally and within Canada
- Identify potential applications for use of the EQ-5D in Alberta as a standardized health outcome measure
- Develop a collaborative research agenda to support broad implementation of the EQ-5D in Alberta
The symposium content was organized around three themes that captured the most common applications of the EQ-5D:
- Clinical health outcomes measurement in research and program evaluation
- Economic analysis of healthcare interventions
- Population health status assessment
Related Methodology Forums:
- Prioritizing Methodological Research in Evaluation of Health Technologies (23 – 24 September 2010)
- Personalized Medicine: Research Challenge – Health Economics Methodology (11 – 12 January 2012)
The methodology forum series is supported through funding and in kind support from the Alberta Government, the Canadian Agency for Drugs and Technologies in Health (CADTH), the National Institute for Health and Clinical Excellence (NICE), Merck, GlaxoSmithKline, Pfizer, and Eli Lilly, and AstraZeneca.